North American Study of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)
North American Study of Epistaxis in HHT (NOSE)
Sponsor: HHT Foundation International
A PHASE2 clinical study on Epistaxis and Telangiectasia, Hereditary Hemorrhagic, this trial is completed. The trial is conducted by HHT Foundation International and has accumulated 9 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE2
▶ Show 4 earlier versions
-
Nov 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Nov 2018 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Aug 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- HHT Foundation International
- James Gossage
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Augusta, United States
- • Baltimore, United States
- • Los Angeles, United States
- • Portland, United States
- • Salt Lake City, United States
- • St Louis, United States